标题
TMC435 for the treatment of chronic hepatitisC
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 8, Pages 1193-1209
出版商
Informa Healthcare
发表日期
2012-05-23
DOI
10.1517/13543784.2012.690392
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
- (2011) Michael Manns et al. ANTIVIRAL THERAPY
- Second-wave Protease Inhibitors: Choosing an Heir
- (2011) Sandra Ciesek et al. Clinics in Liver Disease
- The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending
- (2011) Jean–Michel Pawlotsky GASTROENTEROLOGY
- 1221 TREATMENT OUTCOME AND RESISTANCE ANALYSIS IN HCV GENOTYPE 1 PATIENTS PREVIOUSLY EXPOSED TO TMC435 MONOTHERAPY AND RE-TREATED WITH TMC435 IN COMBINATION WITH PEGIFNα-2A/RIBAVIRIN
- (2011) O. Lenz et al. JOURNAL OF HEPATOLOGY
- 11 IMPACT OF IL28B GENOTYPE AND PRETREATMENT SERUM IP-10 IN TREATMENT-NAIVE GENOTYPE-1 HCV PATIENTS TREATED WITH TMC435 IN COMBINATION WITH PEGINTERFERONa-2A AND RIBAVIRIN IN PILLAR STUDY
- (2011) J. Aerssens et al. JOURNAL OF HEPATOLOGY
- 1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT
- (2011) S. Zeuzem et al. JOURNAL OF HEPATOLOGY
- 472 PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
- (2011) V. Sekar et al. JOURNAL OF HEPATOLOGY
- 8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS
- (2011) J.C. Sullivan et al. JOURNAL OF HEPATOLOGY
- Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients
- (2011) Edward J. Gane et al. JOURNAL OF HEPATOLOGY
- Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
- (2011) Philippe Halfon et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
- (2011) Kenneth E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target
- (2010) Maxwell D. Cummings et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
- (2010) O. Lenz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 759 COMBINATION OF TMC435 WITH TWO NOVEL NS5B INHIBITORS INCREASES ANTI HCV ACTIVITY AND RESULTS IN A HIGHER GENETIC BARRIER IN VITRO
- (2010) O. Lenz et al. JOURNAL OF HEPATOLOGY
- Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
- (2010) Michael P. Manns et al. JOURNAL OF HEPATOLOGY
- In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
- (2009) T.-I Lin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
- (2009) N. J. Liverton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Perspectives on the management of chronic hepatitis B and C
- (2009) Geoffrey M Dusheiko et al. Expert Review of Anti-Infective Therapy
- Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
- (2009) Henk W. Reesink et al. GASTROENTEROLOGY
- Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis
- (2009) Savino Bruno et al. HEPATOLOGY
- 1058 ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY
- (2009) P. Marcellin et al. JOURNAL OF HEPATOLOGY
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
- (2008) Pierre Raboisson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
- (2008) V. Soriano et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The exploration of macrocycles for drug discovery — an underexploited structural class
- (2008) Edward M. Driggers et al. NATURE REVIEWS DRUG DISCOVERY
- Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
- (2007) Maria Cubero et al. VIROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search